Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

64.71 -0.74 (-1.13%)
Delayed Quote Updated: 2:03 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 625,410
Open 65.00
Bid (Size) 64.66 (200)
Ask (Size) 64.77 (100)
Prev. Close 65.45
Today's Range 64.60 - 65.75
52wk Range 33.55 - 95.49
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and... 
Via MarketBeat

Performance

YTD
-4.5%
-4.5%
1 Month
-21.5%
-21.5%
3 Month
-19.6%
-19.6%
6 Month
+2.8%
+2.8%
1 Year
+87.6%
+87.6%

More News

Read More
News headline image
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands ↗
Via MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Flashes Bull Flag Breakout Setup with Top-Tier Technical Strength ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials ↗
Via MarketBeat
News headline image
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session. ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
Via MarketBeat

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 64.71
When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 10/01/26 02:03 PM ET
What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 6.84B
How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
Arrowhead Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.